Evaxion PIONEER - Proprietary AI Platform - Immuno-Oncology Therapy
PIONEER is our proprietary AI platform for the rapid discovery and design of patient-specific neoepitopes used to derive immuno-oncology therapies. It has been shown that neoepitopes, which arise from patient-specific tumor mutations, play a critical role in T-cell mediated antitumor immune response.
-
Most popular related searches
Details
We believe our proprietary in silico AI models within PIONEER enable us to efficiently identify and select those neoepitopes that will generate a de novo T-cell response potentially leading to significant antitumor effect in each patient. Combining these neoepitopes with a purposefully selected delivery modality believed to potentially enhance efficacy. Our goal is to design and deliver our immunotherapies to patients, effectively training their immune systems to target and kill cancer cells with no or very limited adverse effects on healthy non-cancer cells.
Advantages:
- Identification of Therapeutic Neoepitopes: Better anti-tumor effect correlating with de novo T-cell activation
- Speed: Identifies neoepitopes within 24 hours from receipt of patient biopsy sequencing data
- Identification of Therapeutic Patient-Specific Neoepitopes: Unique to patients’ cancer based on HLA subtype
- Identification of Multiple Neoepitopes: Increase therapeutic effect and overcome clonal heterogeneity and tumor immune escape issues
- Strong Clinical Applicability: In accordance with GAMP5 and compliant with cGMP
- Potential for Repeat Use Over Lifetime of Patient’s Cancer Treatment: Targets emerging cancer clones
- Favorable Safety Profile: Deselects harmful neoepitopes limiting off target effects
- Continuous Improvement: Incorporates ongoing data and new features to increase predictive power
Customer reviews
No reviews were found for Evaxion PIONEER - Proprietary AI Platform - Immuno-Oncology Therapy. Be the first to review!